The OSUCCC Microarray Shared Resource (MASR) was established as a """"""""developing"""""""" Shared Resource in 1998 with genome wide expression analysis, and subsequently became a full shared resource in 1999 offering genome wide expression analysis using Affymetrix GeneChips. In November 2004, under the direction of Dr. Cario Croce, the MASR underwent a massive expansion with an infusion of capital from the CCC's institutional resources. Dr. Croce developed and built the first microarray to study microRNAs which has now been utilized by a multitude of OSUCCC investigators, by CCC investigators from the NCI and other NCI-designated cancer centers and by investigators from around the world. In 2008, MASR acquired Agilent and Exiqon microarray platforms. The MASR has thus kept up with the dramatic expansion of demands for nucleic acid-based technologies in cancer research in order to serve CCC members with an outstanding range of expression analyses. For projects utilizing microarray technologies, MASR offers multiple unique, cost effective, and comprehensive state-of-the-art services and experience, including timely experimental design consultation, genome wide expression and SNP/mutation analysis on microarray and on next-generation instrumentation, array comparative genomic hybridization (CGH) assessment of DNA and RNA integrity, quantification of DNA and RNA, design, fabrication and validation of custom microarrays, quality sample processing, hybridization, and scanning. Microarray analysis supports studies of the diverse genetic profile of cancer including analysis of genomes, epigenomes and transcriptomes in murine and human systems including both normal and malignant tissues from cancer patients. MASR uses CAarray and trains investigators to upload results to Gene Expression Omnibus (http//www/ncbi.nim.nih.gov/geo). Through outstanding institutional support and leveraging of CCSG resources, MASR has developed into a robust centralized shared resource serving the needs of OSUCCC investigators, cancer researchers in the state of Ohio, and nationally with multiple NCI cancer centers. As predicted in our last review, regular usage of the MASR has grown by over 100%, in part the result of a $2.0 m in capital investment by the CCC into the MASR equipment using institutional support. During the past 12 months, the faculty and staff of the MASR have worked with 52 OSUCCC members coming from five of the six OSUCCC scientific programs. OSUCCC members with peer-reviewed funded accounted for 71.8% of the MASR usage;overall OSUCCC usage is 88.9%. These past 12 months indicate a continuous robust demand for MASR services and predict expanded demand for MASR services.
The Microarray Shared Resource (MASR) offers unique, cost-effective, and timely technical and professional expertise that promotes high-quality science. Services include: timely experimental design consultation, genome wide expression and SNP/mutation analysis on microarray and on nextgeneration instrumentation, array comparative genomic hybridization (CGH) assessment of DNA and RNA integrity, quantification of DNA and RNA, design, fabrication and validation of custom microarrays, quality sample processing, hybridization, and scanning. Outstanding institutional support allows the MASR to contribute to cutting edge-cancer research that integrates OSUCCC investigations across the entire University, state of Ohio, and nationally with multiple NCI Cancer Centers.
|Chen, Xiang; Wei, Jia; Li, Chenglong et al. (2018) Blocking interleukin-6 signaling inhibits cell viability/proliferation, glycolysis, and colony forming activity of human medulloblastoma cells. Int J Oncol 52:571-578|
|Poorman, Caroline E; Ethun, Cecilia G; Postlewait, Lauren M et al. (2018) A Novel T-Stage Classification System for Adrenocortical Carcinoma: Proposal from the US Adrenocortical Carcinoma Study Group. Ann Surg Oncol 25:520-527|
|Stover, Daniel G; Gil Del Alcazar, Carlos R; Brock, Jane et al. (2018) Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer 4:10|
|van Oosterwijk, Jolieke G; Buelow, Daelynn R; Drenberg, Christina D et al. (2018) Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. J Clin Invest 128:369-380|
|Das Ghatak, Piya; Mathew-Steiner, Shomita S; Pandey, Priyanka et al. (2018) A surfactant polymer dressing potentiates antimicrobial efficacy in biofilm disruption. Sci Rep 8:873|
|Bhattacharya, Mohini; Berends, Evelien T M; Chan, Rita et al. (2018) Staphylococcus aureus biofilms release leukocidins to elicit extracellular trap formation and evade neutrophil-mediated killing. Proc Natl Acad Sci U S A 115:7416-7421|
|Kodigepalli, Karthik M; Li, Minghua; Bonifati, Serena et al. (2018) SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice. Cell Cycle 17:2564-2576|
|Woodard, John L; Huntsman, Andrew C; Patel, Pratiq A et al. (2018) Synthesis and antiproliferative activity of derivatives of the phyllanthusmin class of arylnaphthalene lignan lactones. Bioorg Med Chem 26:2354-2364|
|Miller, Katherine E; Kelly, Benjamin; Fitch, James et al. (2018) Genome sequencing identifies somatic BRAF duplication c.1794_1796dupTAC;p.Thr599dup in pediatric patient with low-grade ganglioglioma. Cold Spring Harb Mol Case Stud 4:|
|Ghonime, Mohammed G; Jackson, Josh; Shah, Amish et al. (2018) Chimeric HCMV/HSV-1 and ??134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory. Transl Oncol 11:86-93|
Showing the most recent 10 out of 2602 publications